LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
We assign a fundamental rating of 3 out of 10 to LYEL. LYEL was compared to 564 industry peers in the Biotechnology industry. While LYEL has a great health rating, there are worries on its profitability. LYEL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year LYEL has reported negative net income.
LYEL had a negative operating cash flow in the past year.
LYEL had negative earnings in each of the past 5 years.
LYEL had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -32.94%, LYEL is in the better half of the industry, outperforming 64.81% of the companies in the same industry.
LYEL has a better Return On Equity (-38.44%) than 73.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.94% | ||
| ROE | -38.44% | ||
| ROIC | N/A |
ROA(3y)-24.34%
ROA(5y)-23.76%
ROE(3y)-28.24%
ROE(5y)-28.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LYEL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYEL has more shares outstanding than it did 1 year ago.
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
LYEL has an Altman-Z score of -1.69. This is a bad value and indicates that LYEL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LYEL (-1.69) is comparable to the rest of the industry.
LYEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.69 |
ROIC/WACCN/A
WACC10.59%
2.3 Liquidity
A Current Ratio of 13.43 indicates that LYEL has no problem at all paying its short term obligations.
With an excellent Current ratio value of 13.43, LYEL belongs to the best of the industry, outperforming 87.61% of the companies in the same industry.
LYEL has a Quick Ratio of 13.43. This indicates that LYEL is financially healthy and has no problem in meeting its short term obligations.
LYEL has a Quick ratio of 13.43. This is amongst the best in the industry. LYEL outperforms 87.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.43 | ||
| Quick Ratio | 13.43 |
3. Growth
3.1 Past
The earnings per share for LYEL have decreased strongly by -27.42% in the last year.
The Revenue for LYEL has decreased by -99.87% in the past year. This is quite bad
Measured over the past years, LYEL shows a very negative growth in Revenue. The Revenue has been decreasing by -74.41% on average per year.
EPS 1Y (TTM)-27.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y-74.41%
Revenue growth 5YN/A
Sales Q2Q%36%
3.2 Future
LYEL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.64% yearly.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y-2%
EPS Next 2Y-4.81%
EPS Next 3Y0.64%
EPS Next 5YN/A
Revenue Next Year-98.94%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LYEL. In the last year negative earnings were reported.
Also next year LYEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.81%
EPS Next 3Y0.64%
5. Dividend
5.1 Amount
LYEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LYELL IMMUNOPHARMA INC
NASDAQ:LYEL (1/2/2025, 4:10:28 PM)
After market: 0.645 0 (0%)0.645
+0.01 (+0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners61.34%
Inst Owner Change-4.1%
Ins Owners2%
Ins Owner Change0%
Market Cap188.44M
Analysts46.67
Price Target1.02 (58.14%)
Short Float %4.71%
Short Ratio6.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.29%
Min EPS beat(2)13.92%
Max EPS beat(2)16.67%
EPS beat(4)3
Avg EPS beat(4)8.13%
Min EPS beat(4)-12.04%
Max EPS beat(4)16.67%
EPS beat(8)7
Avg EPS beat(8)26.1%
EPS beat(12)10
Avg EPS beat(12)21.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-72.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.06%
EPS NY rev (1m)0%
EPS NY rev (3m)6.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)175%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2991.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.36 | ||
| P/tB | 0.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.94% | ||
| ROE | -38.44% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-24.34%
ROA(5y)-23.76%
ROE(3y)-28.24%
ROE(5y)-28.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.27% | ||
| Cap/Sales | 707.94% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.43 | ||
| Quick Ratio | 13.43 | ||
| Altman-Z | -1.69 |
F-Score2
WACC10.59%
ROIC/WACCN/A
Cap/Depr(3y)209.64%
Cap/Depr(5y)620.54%
Cap/Sales(3y)903.28%
Cap/Sales(5y)1161.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-2%
EPS Next 2Y-4.81%
EPS Next 3Y0.64%
EPS Next 5YN/A
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y-74.41%
Revenue growth 5YN/A
Sales Q2Q%36%
Revenue Next Year-98.94%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-7.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.96%
EBIT Next 3Y-8.65%
EBIT Next 5YN/A
FCF growth 1Y18.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.13%
OCF growth 3YN/A
OCF growth 5YN/A